Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room
Simon Eckermann,Brita Pekarsky +1 more
Reads0
Chats0
TLDR
This work critically examines the conditions under which displaced services would represent an economically meaningful threshold value for the effects of a new technology as part of a reimbursement process when budgets are fixed and identifies the most cost-effective alternative strategy for reimbursement.Abstract:
In current literature, displaced services have been suggested to provide a basis for determining a threshold value for the effects of a new technology as part of a reimbursement process when budgets are fixed. We critically examine the conditions under which displaced services would represent an economically meaningful threshold value. We first show that if we assume that the least cost-effective services are displaced to finance a new technology, then the incremental cost-effectiveness ratio (ICER) of the displaced services (d) only coincides with that related to the opportunity cost of adopting that new technology, the ICER of the most cost-effective service in expansion (n), under highly restrictive conditions—namely, complete allocative efficiency in existing provision of health care interventions. More generally, reimbursement of new technology with a fixed budget comprises two actions; adoption and financing through displacement and the effect of reimbursement is the net effect of these two actions. In order for the reimbursement process to be a pathway to allocative efficiency within a fixed budget, the net effect of the strategy of reimbursement is compared with the most cost-effective alternative strategy for reimbursement: optimal reallocation, the health gain maximizing expansion of existing services financed by the health loss minimizing contraction. The shadow price of the health effects of a new technology, \( \beta_{c} = \left( {\frac{1}{n} + \frac{1}{d} - \frac{1}{m}} \right)^{ - 1} , \) accounts for both imperfect displacement (the ICER of the displaced service, d < m, the ICER of the least cost-effective of the existing services in contraction) and the allocative inefficiency (n < m) characteristic of health systems.read more
Citations
More filters
Journal ArticleDOI
Cost effectiveness thresholds: the past, the present and the future
TL;DR: The meaning of a CE threshold and the key assumptions involved are highlighted, the use of historic/heuristic estimates of the threshold are noted along with their limitations, and a number of common issues and misconceptions associated with CE thresholds are addressed.
Journal ArticleDOI
Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use
TL;DR: It must be possible to compare interventions in terms of their impact on a common measure of health; mere effectiveness is not a persuasive case for inclusion in public insurance plans; public health advocates need to address issues of relative effectiveness.
Journal ArticleDOI
A new proposal for priority setting in Norway: Open and fair
Trygve Ottersen,Reidun Førde,Meetali Kakad,Alice Kjellevold,Hans Olav Melberg,Atle Moen,Ånen Ringard,Ole Frithjof Norheim +7 more
TL;DR: The new, comprehensive framework for priority setting recently laid out by the third Norwegian Committee on Priority Setting in the Health Sector posits that priority setting should pursue the goal of "the greatest number of healthy life years for all, fairly distributed".
Journal ArticleDOI
Opportunity Cost of Funding Drugs for Rare Diseases: The Cost-Effectiveness of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
TL;DR: This study demonstrates the feasibility of conducting economic evaluations in the context of rare diseases by demonstrating the cost-effectiveness of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and its associated opportunity costs.
Journal ArticleDOI
Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.
TL;DR: Comparison in CDU space and associated summary measures have distinct advantages to multiple domain comparisons, aiding transparent and robust joint comparison of costs and multiple effects under uncertainty across potential threshold values for effect, better informing net benefit assessment and related reimbursement and research decisions.
References
More filters
Posted Content
Methods for the Economic Evaluation of Health Care Programmes
TL;DR: The fourth edition of the Methods for the Economic Evaluation of Health Care Programmes as mentioned in this paper has been thoroughly revised and updated, making it essential reading for anyone commissioning, undertaking, or using economic evaluations in health care, including health service professionals, health economists, and health care decision makers.
Journal ArticleDOI
Methods for the economic evaluation of health care programmes
TL;DR: Using archival material supplemented by interviews with community physicians, Jane Lewis shows how 'public health' and 'preventive medicine' have been supplanted as the central concern of medicine by curative and acute specialties.
Journal ArticleDOI
Uncertainty and the welfare economics of medical care
TL;DR: This chapter focuses on the way in which the operation of the medical-care industry and the efficacy with which it satisfies the needs of society differ from a norm.
Journal ArticleDOI
The NICE cost-effectiveness threshold: what it is and what that means.
TL;DR: It is feasible and probably desirable to operate an explicit single threshold rather than the current range and the development of a programme of disinvestment guidance would enable NICE and the NHS to be more confident that the net health benefit of the Technology Appraisal Programme is positive.
Journal ArticleDOI
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
Karl Claxton,Stephen Martin,Marta Soares,Nigel Rice,Eldon Spackman,Sebastian Hinde,Nancy Devlin,Peter C. Smith,Mark Sculpher +8 more
TL;DR: The methods go some way to providing an empirical estimate of the scale of opportunity costs the NHS faces when considering whether or not the health benefits associated with new technologies are greater than the health that is likely to be lost elsewhere in the NHS.
Related Papers (5)
Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis
Nancy Devlin,David Parkin +1 more